Protracted withdrawal syndromes from benzodiazepines
The DOI matches its Crossref record; 55 of the 59 references it cites were found in a registry or an index.
Abstract
The benzodiazepine withdrawal syndrome is a complex phenomenon which presents serious difficulties in definition and measurement. It is particularly difficult to set out precise limits on its duration. Many withdrawal symptoms are a result of pharmacodynamic tolerance to benzodiazepines, some mechanisms for which are discussed. Such tolerance develops unevenly in different brain systems and may be slow to reverse. Withdrawal symptoms occurring in the first week after cessation of drug use tend to merge with more persistent symptoms that may last for many months. These prolonged symptoms do not necessarily constitute "true" pharmacological withdrawal symptoms, but are nevertheless related to long-term benzodiazepine use. Such symptoms can include anxiety, which may partly result from a learning deficit imposed by the drugs, and a variety of sensory and motor neurological symptoms. The protracted nature of some of these symptoms raises the possibility that benzodiazepines can give rise not only to slowly reversible functional changes in the central nervous system, but may also occasionally cause structural neuronal damage.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neurologic, gastrointestinal, cutaneous, psychological, and other symptoms have been reported [15].”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [15]
In the citing paper
“As a result, determining whether a patient is at risk of withdrawal is not always clear (see Table 3).78”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [78]
In the citing paper
“Protracted symptoms persist beyond the expected elimination of the BZD from a patient’s system after discontinuation (e.g., 4–6 weeks), with some patients experiencing these symptoms for months or years.78,130,132”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [78]
In the citing paper
“Rebound anxiety can also occur during ongoing treatment with rapidly eliminated benzodiazepines when their pharmacological effects decrease.”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [36]
In the citing paper
“The prolonged use of antidepressant medications, similar to other psychotropic substances, can lead to sustained neurophysiological adaptations (Ashton, 1991; Cosci and Chouinard, 2020; Fava and Cosci, 2019; Horowitz et al., 2023; Lerner and Klein, 2019).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Ashton, 1991
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
McMahon, F. G. (1986) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1986.35.673 · Cited by 2,215
Benzodiazepine Receptor: Demonstration in the Central Nervous System
Möhler, H., & Okada, T. (1977) · Science · doi:10.1126/science.918669 · Cited by 1,700
Benzodiazepine receptors in rat brain
SQUIRES, R. F., & BRAESTRUP, C. (1977) · Nature · doi:10.1038/266732a0 · Cited by 1,449
Stahl, S. M., Iversen, S. D., & Goodman, E. C. (1989) · International Clinical Psychopharmacology · doi:10.1097/00004850-198910000-00009 · Cited by 482
Radiohistochemical localization of benzodiazepine receptors in rat brain.
Young, W. S., & Kuhar, M. J. (1980) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)31961-0 · Cited by 390
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Withdrawal from long-term benzodiazepine treatment
Petursson, H., & Lader, M. H. (1981) · BMJ · doi:10.1136/bmj.283.6292.643 · Cited by 367
The neuropsychology of emotion and personality.
Gray, J. A. (1987) · Cited by 317
Benzodiazepine withdrawal symptoms and propranolol
TYRER, P. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92861-0 · Cited by 297
Research works printed but not linked: 1
- Sepinwall, 1979, Mechanisms of action of the benzodiazepines: Behavioural aspects, Federation Proceedings, 39, 3024
Cited by
Guidelines for the Rational Use of Benzodiazepines: When and What to Use
Ashton, H. (1994) · Drugs · doi:10.2165/00003495-199448010-00004 · Cited by 593
“In the majority of cases, symptoms gradually improve after withdrawal[55,80] although some pa-”
BackgroundSelf-citationComorbidity of insomnia and depression
Staner, L. (2010) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2009.09.003 · Cited by 481
Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives.
Longo, L. P., & Johnson, B. (2000) · PubMed · Cited by 420
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Metadata
- Authors
- Ashton, H.
- Affiliations
- Newcastle University (GB)
- Corresponding author
- Ashton, Heather
- Venue
- Journal of Substance Abuse Treatment
- Publisher
- Elsevier BV
- Published
- 1991-01
- Volume
- 8
- Issue
- 1-2
- Pages
- 19-28
- ISSN
- 0740-5472 (ISSN-L)
- OpenAlex
- W2160562969
- Semantic Scholar
- 00545ce6429465e1810207f90324360af8e03ad7
- Cited by
- 170
- References
- 59
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 8 · 2023: 7 · 2022: 9 · 2021: 16 · 2020: 12 · 2019: 7 · 2018: 4 · 2017: 4 · 2016: 3 · 2015: 7 · 2014: 3 · 2013: 3 · 2012: 8
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Substance Abuse Treatment (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- benzodiazepine withdrawal syndrome, long-term benzodiazepine use, anxiety, neuronal injury
- MeSH terms
- Aged, Benzodiazepines, Dose-Response Relationship, Drug, Drug Tolerance, Female, Humans, Middle Aged, Neurologic Examination, Substance Withdrawal Syndrome, Anti-Anxiety Agents, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protracted withdrawal syndromes from benzodiazepines. https://app.cochat.ai/papers/10.1016/0740-5472(91)90023-4
- The paper
- Ashton, H. (1991). Protracted withdrawal syndromes from benzodiazepines. Journal of Substance Abuse Treatment. https://doi.org/10.1016/0740-5472(91)90023-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.